Reviews
Shengzheng Wang, Guoqiang Dong, Chunquan Sheng. Structural simplification:an efficient strategy in lead optimization[J]. Acta Pharmaceutica Sinica B, 2019, 9(5): 880-901

Structural simplification:an efficient strategy in lead optimization
Shengzheng Wanga,b, Guoqiang Donga, Chunquan Shenga
a Department of Medicinal Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China;
b Department of Medicinal Chemistry and Pharmaceutical Analysis, School of Pharmacy, Fourth Military Medical University, Xi'an 710032, China
Abstract:
The trend toward designing large hydrophobic molecules for lead optimization is often associated with poor drug-likeness and high attrition rates in drug discovery and development. Structural simplification is a powerful strategy for improving the efficiency and success rate of drug design by avoiding "molecular obesity". The structural simplification of large or complex lead compounds by truncating unnecessary groups can not only improve their synthetic accessibility but also improve their pharmacokinetic profiles, reduce side effects and so on. This review will summarize the application of structural simplification in lead optimization. Numerous case studies, particularly those involving successful examples leading to marketed drugs or drug-like candidates, will be introduced and analyzed to illustrate the design strategies and guidelines for structural simplification.
Key words:    Structural simplification    Lead optimization    Drug discovery    Drug design    Reducing rings number    Reducing chiral centers    Structure-based simplification    Pharmacophore-based simplification   
Received: 2019-03-05     Revised: 2019-05-04
DOI: 10.1016/j.apsb.2019.05.004
Funds: This work was supported by the National Natural Science Foundation of China (Grant No. 81725020 to Chunquan Sheng and No. 21602252 to Shengzheng Wang), the Innovation Program of Shanghai Municipal Education Commission (Grant No. 2019-01-07-00-07-E00073 to Chunquan Sheng, China), and the Hong Kong Scholars Program (Grant No. XJ201713 to Shengzheng Wang, China).
Corresponding author: Guoqiang Dong, Chunquan Sheng     Email:dgq-81@163.com;shengcq@smmu.edu.cn
Author description:
Service
PDF(KB) Free
Print
0
Authors
Shengzheng Wang
Guoqiang Dong
Chunquan Sheng

References:
1. Mignani S, Huber S, Tomás H, Rodrigues J, Majoral JP. Compound high-quality criteria:a new vision to guide the development of drugs, current situation. Drug Discov Today 2016;21:573-84.
2. Polanski J, Bogocz J, Tkocz A. The analysis of the market success of FDA approvals by probing top 100 bestselling drugs. J Comput Aided Mol Des 2016;30:381-9.
3. Keser} u GM, Makara GM. Hit discovery and hit-to-lead approaches. Drug Discov Today 2006;11:741-8.
4. Walters WP, Green J, Weiss JR, Murcko MA. What do medicinal chemists actually make? A 50-year retrospective. J Med Chem 2011; 54:6405-16.
5. Oprea TI, Davis AM, Teague SJ, Leeson PD. Is there a difference between leads and drugs? A historical perspective. J Chem Inf Comput Sci 2001;41:1308-15.
6. Manly CJ, Chandrasekhar J, Ochterski JW, Hammer JD, Warfield BB. Strategies and tactics for optimizing the Hit-to-Lead process and beyondda computational chemistry perspective. Drug Discov Today 2008;13:99-109.
7. Hann MM. Molecular obesity, potency and other addictions in drug discovery. MedChemComm 2011;2:349-55.
8. Hann MM, Keserü GM. Finding the sweet spot:the role of nature and nurture in medicinal chemistry. Nat Rev Drug Discov 2012;11:355-65.
9. Maynard AT, Roberts CD. Quantifying, visualizing, and monitoring lead optimization. J Med Chem 2016;59:4189-201.
10. Böttcher T. An additive definition of molecular complexity. J Chem Inf Model 2016;56:462-70.
11. Hann MM, Leach AR, Harper G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comput Sci 2001;41:856-64.
12. Méndez-Lucio O, Medina-Franco JL. The many roles of molecular complexity in drug discovery. Drug Discov Today 2017;22:120-6.
13. Crane EA, Gademann K. Capturing biological activity in natural product fragments by chemical synthesis. Angew Chem Int Ed Engl 2016;55:3882-902.
14. Guo Z. The modification of natural products for medical use. Acta Pharm Sin B 2017;7:119-36.
15. Xiao Z, Morris-Natschke SL, Lee KH. Strategies for the optimization of natural leads to anticancer drugs or drug candidates. Med Res Rev 2016;36:32-91.
16. Rodrigues T, Reker D, Schneider P, Schneider G. Counting on natural products for drug design. Nat Chem 2016;8:531-41.
17. Blakemore PR, White JD. Morphine, the Proteus of organic molecules. Chem Commun 2002;11:1159-68.
18. Gudin J, Fudin J, Nalamachu S. Levorphanol use:past, present and future. Postgrad Med 2016;128:46-53.
19. Heel RC, Brogden RN, Speight TM, Avery GS. Butorphanol:a review of its pharmacological properties and therapeutic efficacy. Drugs 1978;16:473-505.
20. Commiskey S, Fan LW, Ho IK, Rockhold RW. Butorphanol:effects of a prototypical agonist-antagonist analgesic on k-opioid receptors. J Pharmacol Sci 2005;98:109-16.
21. Aarnes TK, Muir Ⅲ WW. Chapter 26dpain assessment and management. In:Peterson ME, Kutzler MA, editors. Small animal pediatrics. Saint Louis:W.B. Saunders; 2011. p. 220-32.
22. Prezzavento O, Arena E, Sánchez-Fernández C, Turnaturi R, Parenti C, Marrazzo A, et al. (+)-and (-)-Phenazocine enantiomers:evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects. Eur J Med Chem 2017;125:603-10.
23. Levine JD, Gordon NC. Synergism between the analgesic actions of morphine and pentazocine. Pain 1988;33:369-72.
24. Ziering A, Lee J. Piperidine derivatives. V. 1,3-Dialkyl-4-aryl-4-acyloxypiperidines. J Org Chem 1947;12:911-4.
25. Van Bever WF, Niemegeers CJ, Janssen PA. Synthetic analgesics. Synthesis and pharmacology of the diastereoisomers of N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide and N-[3-methyl-1-(1-methyl-2-phenylethyl)-4-piperidyl]-N-phenylpropanamide. J Med Chem 1974;17:1047-51.
26. Barnett CJ. Modification of methadone synthesis process step. US patent 4048211A. 1977 Sep 13.
27. King JA, Meltzer RI, Doczi J. The synthesis of some fluorene derivatives. J Am Chem Soc 1955;77:2217-23.
28. Corbett AD, Paterson SJ, Kosterlitz HW. Selectivity of ligands for opioid receptors. In:Herz A, Akil H, Simon EJ, editors. Opioids. Berlin, Heidelberg:Springer; 1993. p. 645-79.
29. Wang S, Dong G, Sheng C. Structural simplification of natural products. Chem Rev 2019;119:4180-220.
30. Uemura D, Takahashi K, Yamamoto T, Katayama C, Tanaka J, Okumura Y, et al. Norhalichondrin A:an antitumor polyether macrolide from a marine sponge. J Am Chem Soc 1985;107:4796-8.
31. Hirata Y, Uemura D. Halichondrinsdantitumor polyether macrolides from a marine sponge. Pure Appl Chem 1986;58:701-10.
32. Bai RL, Paull KD, Herald CL, Malspeis L, Pettit GR, Hamel E. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 1991;266:15882-9.
33. Aicher TD, Buszek KR, Fang FG, Forsyth CJ, Jung SH, Kishi Y, et al. Total synthesis of halichondrin B and norhalichondrin B. J Am Chem Soc 1992;114:3162-4.
34. Jackson KL, Henderson JA, Phillips AJ. The halichondrins and E7389. Chem Rev 2009;109:3044-79.
35. Zheng W, Seletsky BM, Palme MH, Lydon PJ, Singer LA, Chase CE, et al. Macrocyclic ketone analogues of halichondrin B. Bioorg Med Chem Lett 2004;14:5551-4.
36. Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001;61:1013-21.
37. Donoghue M, Lemery SJ, Yuan W, He K, Sridhara R, Shord S, et al. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer:use of a "physician's choice" control arm in a randomized approval trial. Clin Cancer Res 2012;18:1496-505.
38. Fujita T, Hirose R, Hamamichi N, Kitao Y, Sasaki S, Yoneta M, et al. 2-Substituted 2-aminoethanol:minimum essential structure for immunosuppressive activity of ISP-I (myriocin). Bioorg Med Chem Lett 1995;5:1857-60.
39. Sasaki S, Hashimoto R, Kiuchi M, Inoue K, Ikumoto T, Hirose R, et al. Fungal metabolites. Part 14. Novel potent immunosuppressants, mycestericins, produced by Mycelia sterilia. J Antibiot (Tokyo) 1994; 47:420-33.
40. Fujita T, Yoneta M, Hirose R, Sasaki S, Inoue K, Kiuchi M, et al. Simple compounds, 2-alkyl-2-amino-1,3-propanediols have potent immunosuppressive activity. Bioorg Med Chem Lett 1995;5:847-52.
41. Yoshida M, Horinouchi S, Beppu T. Trichostatin A and trapoxin:novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 1995;17:423-30.
42. Huang Y, Dong G, Li H, Liu N, Zhang W, Sheng C. Discovery of janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors as a novel strategy for the combinational treatment of leukemia and invasive fungal infections. J Med Chem 2018;61:6056-74.
43. Stowell JC, Huot RI, Van Voast L. The synthesis of N-hydroxy-N'-phenyloctanediamide and its inhibitory effect on proliferation of AXC rat prostate cancer cells. J Med Chem 1995;38:1411-3.
44. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary:vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncol 2007;12:1247-52.
45. Liu GT. Bicyclol:a novel drug for treating chronic viral hepatitis B and C. Med Chem 2009;5:29-43.
46. Liu GT. Therapeutic effects of biphenyl dimethyl dicarboxylate (DDB) on chronic viral hepatitis B. Proc Chin Acad Med Sci Peking Union Med Coll 1987;2:228-33.
47. Liu GT. The anti-virus and hepatoprotective effect of bicyclol and its mechanism of action. Chin J New Drugs 2001;10:325-7.
48. Jirousek MR, Gillig JR, Gonzalez CM, Heath WF, McDonald Ⅲ JH, Neel DA, et al. (S)-13-[(Dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo[e,k]pyrrolo[3,4-h] [1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues:isozyme selective inhibitors of protein kinase Cb. J Med Chem 1996;39:2664-71.
49. Faul MM, Gillig JR, Jirousek MR, Ballas LM, Schotten T, Kahl A, et al. Acyclic N-(azacycloalkyl)bisindolylmaleimides:isozyme selective inhibitors of PKCb. Bioorg Med Chem Lett 2003;13:1857-9.
50. Chang RS, Lotti VJ, Monaghan RL, Birnbaum J, Stapley EO, Goetz MA, et al. A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus. Science 1985;230:177-9.
51. Zucker KA, Adrian TE, Zdon MJ, Ballantyne GH, Modlin IM. Asperlicin:a unique nonpeptide cholecystokinin antagonist. Surgery 1987;102:163-70.
52. Evans BE, Bock MG, Rittle KE, DiPardo RM, Whitter WL, Veber DF, et al. Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin. Proc Natl Acad Sci U S A 1986;83:4918-22.
53. Evans BE, Rittle KE, Bock MG, DiPardo RM, Freidinger RM, Whitter WL, et al. Design of nonpeptidal ligands for a peptide receptor:cholecystokinin antagonists. J Med Chem 1987;30:1229-39.
54. Evans BE, Rittle KE, Bock MG, DiPardo RM, Freidinger RM, Whitter WL, et al. Methods for drug discovery:development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem 1988;31:2235-46.
55. Weber L. The application of multi-component reactions in drug discovery. Curr Med Chem 2002;9:2085-93.
56. Magedov IV, Frolova L, Manpadi M, Bhoga UD, Tang H, Evdokimov NM, et al. Anticancer properties of an important drug lead podophyllotoxin can be efficiently mimicked by diverse heterocyclic scaffolds accessible via one-step synthesis. J Med Chem 2011;54:4234-46.
57. Evdokimov NM, Van Slambrouck S, Heffeter P, Tu L, Le Calvé B, Lamoral-Theys D, et al. Structural simplification of bioactive natural products with multicomponent synthesis. 3. Fused uracil-containing heterocycles as novel topoisomerase-targeting agents. J Med Chem 2011;54:2012-21.
58. Magedov IV, Manpadi M, Ogasawara MA, Dhawan AS, Rogelj S, Van Slambrouck S, et al. Structural simplification of bioactive natural products with multicomponent synthesis. 2. Antiproliferative and antitubulin activities of pyrano[3,2-c]pyridones and pyrano[3,2-c] quinolones. J Med Chem 2008;51:2561-70.
59. Soria-Mercado IE, Prieto-Davo A, Jensen PR, Fenical W. Antibiotic terpenoid chloro-dihydroquinones from a new marine actinomycete. J Nat Prod 2005;68:904-10.
60. Hussain H, Krohn K, Ahmad VU, Miana GA. Green IR. Lapachol:an overview. Arkivoc 2007;2:145-71.
61. Siripong P, Kanokmedakul K, Piyaviriyagul S, Yahuafai J, Chanpai R, Ruchirawat S, et al. Antiproliferative naphthoquinone esters from Rhinacanthus nasutus Kurz. roots on various cancer cells. J Tradit Med 2006;23:166-72.
62. Magedov IV, Kireev AS, Jenkins AR, Evdokimov NM, Lima DT, Tongwa P, et al. Structural simplification of bioactive natural products with multicomponent synthesis. 4. 4H-pyrano-[2,3-b]naphthoquinones with anticancer activity. Bioorg Med Chem Lett 2012; 22:5195-8.
63. Over B, Wetzel S, Grütter C, Nakai Y, Renner S, Rauh D, et al. Natural-product-derived fragments for fragment-based ligand discovery. Nat Chem 2013;5:21-8.
64. Grabowski K, Baringhaus KH, Schneider G. Scaffold diversity of natural products:inspiration for combinatorial library design. Nat Prod Rep 2008;25:892-904.
65. Bon RS, Waldmann H. Bioactivity-guided navigation of chemical space. Acc Chem Res 2010;43:1103-14.
66. Lachance H, Wetzel S, Kumar K, Waldmann H. Charting, navigating, and populating natural product chemical space for drug discovery. J Med Chem 2012;55:5989-6001.
67. Barelier S, Eidam O, Fish I, Hollander J, Figaroa F, Nachane R, et al. Increasing chemical space coverage by combining empirical and computational fragment screens. ACS Chem Biol 2014;9:1528-35.
68. Reutlinger M, Rodrigues T, Schneider P, Schneider G. Multi-objective molecular de novo design by adaptive fragment prioritization. Angew Chem Int Ed Engl 2014;53:4244-8.
69. Jin X, Lee K, Kim NH, Kim HS, Yook JI, Choi J, et al. Natural products used as a chemical library for protein-protein interaction targeted drug discovery. J Mol Graph Model 2018;79:46-58.
70. Koch MA, Schuffenhauer A, Scheck M, Wetzel S, Casaulta M, Odermatt A, et al. Charting biologically relevant chemical space:a structural classification of natural products (SCONP). Proc Natl Acad Sci U S A 2005;102:17272-7.
71. Schuffenhauer A, Ertl P, Roggo S, Wetzel S, Koch MA, Waldmann H. The scaffold treedvisualization of the scaffold universe by hierarchical scaffold classification. J Chem Inf Model 2007; 47:47-58.
72. Balamurugan R, Dekker FJ, Waldmann H. Design of compound libraries based on natural product scaffolds and protein structure similarity clustering (PSSC). Mol Biosyst 2005;1:36-45.
73. Renner S, van Otterlo WA, Dominguez Seoane MD, Möcklinghoff S, Hofmann B, Wetzel S, et al. Bioactivity-guided mapping and navigation of chemical space. Nat Chem Biol 2009;5:585-92.
74. Wetzel S, Klein K, Renner S, Rauh D, Oprea TI, Mutzel P, et al. Interactive exploration of chemical space with Scaffold Hunter. Nat Chem Biol 2009;5:581-3.
75. Prescher H, Koch G, Schuhmann T, Ertl P, Bussenault A, Glick M, et al. Construction of a 3D-shaped, natural product like fragment library by fragmentation and diversification of natural products. Bioorg Med Chem 2017;25:921-5.
76. Wetzel S, Bon RS, Kumar K, Waldmann H. Biology-oriented synthesis. Angew Chem Int Ed Engl 2011;50:10800-26.
77. van Hattum H, Waldmann H. Biology-oriented synthesis:harnessing the power of evolution. J Am Chem Soc 2014;136:11853-9.
78. Laraia L, Waldmann H. Natural product inspired compound collections:evolutionary principle, chemical synthesis, phenotypic screening, and target identification. Drug Discov Today Technol 2017;23:75-82.
79. Galliford CV, Scheidt KA. Pyrrolidinyl-spirooxindole natural products as inspirations for the development of potential therapeutic agents. Angew Chem Int Ed Engl 2007;46:8748-58.
80. Antonchick AP, Gerding-Reimers C, Catarinella M, Schürmann M, Preut H, Ziegler S, et al. Highly enantioselective synthesis and cellular evaluation of spirooxindoles inspired by natural products. Nat Chem 2010;2:735-40.
81. Funel-Le Bon C, Berrué F, Thomas OP, Reyes F, Amade P, Sodwanone S. A triterpene from the marine sponge Axinella weltneri. J Nat Prod 2005;68:1284-7.
82. Basu S, Ellinger B, Rizzo S, Deraeve C, Schürmann M, Preut H, et al. Biology-oriented synthesis of a natural-product inspired oxepane collection yields a small-molecule activator of the Wntpathway. Proc Natl Acad Sci U S A 2011;108:6805-10.
83. Orosz F, Horvath I, Ovadi J. New anti-mitotic drugs with distinct anti-calmodulin activity. Mini Rev Med Chem 2006;6:1145-57.
84. Dückert H, Pries V, Khedkar V, Menninger S, Bruss H, Bird AW, et al. Natural product-inspired cascade synthesis yields modulators of centrosome integrity. Nat Chem Biol 2011;8:179-84.
85. Peyssonnaux C, Eychène A. The Raf/MEK/ERK pathway:new concepts of activation. Biol Cell 2001;93:53-62.
86. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
87. Singer G, Oldt Ⅲ R, Cohen Y, Wang BG, Sidransky D, Kurman RJ, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003;95:484-6.
88. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 2008;105:3041-6.
89. Stellwagen JC, Adjabeng GM, Arnone MR, Dickerson SH, Han C, Hornberger KR, et al. Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup. Bioorg Med Chem Lett 2011;21:4436-40.
90. Rheault TR, Stellwagen JC, Adjabeng GM, Hornberger KR, Petrov KG, Waterson AG, et al. Discovery of dabrafenib:a selective inhibitor of Raf kinases with antitumor activity against B-Raf-driven Tumors. ACS Med Chem Lett 2013;4:358-62.
91. Zhang C, Spevak W, Zhang Y, Burton EA, Ma Y, Habets G, et al. RAF inhibitors that evade paradoxical MAPK pathway activation. Nature 2015;526:583-6.
92. Wright CJ, McCormack PL. Trametinib:first global approval. Drugs 2013;73:1245-54.
93. Johnston JA, Bacon CM, Riedy MC, O'Shea JJ. Signaling by IL-2 and related cytokines:JAKs, STATs, and relationship to immunodeficiency. J Leukoc Biol 1996;60:441-52.
94. Flanagan ME, Blumenkopf TA, Brissette WH, Brown MF, Casavant JM, Shang-Poa C, et al. Discovery of CP-690,550:a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 2010;53:8468-84.
95. Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, et al. Mutation of Jak3 in a patient with SCID:essential role of Jak3 in lymphoid development. Science 1995;270:797-800.
96. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003;302:875-8.
97. Millan MJ. N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents:novel insights and clinical perspectives. Psychopharmacology 2005;179:30-53.
98. Bergeron R, Meyer TM, Coyle JT, Greene RW. Modulation of Nmethyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci U S A 1998;95:15730-4.
99. Jolidon S, Alberati D, Dowle A, Fischer H, Hainzl D, Narquizian R, et al. Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1. Bioorg Med Chem Lett 2008;18:5533-6.
100. Tepper SJ, Stillman MJ. Clinical and preclinical rationale for CGRPreceptor antagonists in the treatment of migraine. Headache 2008;48:1259-68.
101. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine:a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008;372:2115-23.
102. Wood MR, Schirripa KM, Kim JJ, Quigley AG, Stump CA, Bell IM, et al. Novel CGRP receptor antagonists through a design strategy of target simplification with addition of molecular flexibility. Bioorg Med Chem Lett 2009;19:5787-90.
103. Paone DV, Shaw AW, Nguyen DN, Burgey CS, Deng JZ, Kane SA, et al. Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine:discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-carboxamide (MK-0974). J Med Chem 2007;50:5564-7.
104. Manetti D, Ghelardini C, Bartolini A, Bellucci C, Dei S, Galeotti N, et al. Design, synthesis, and preliminary pharmacological evaluation of 1,4-diazabicyclo[4.3.0]nonan-9-ones as a new class of highly potent nootropic agents. J Med Chem 2000;43:1969-74.
105. Manetti D, Ghelardini C, Bartolini A, Dei S, Galeotti N, Gualtieri F, et al. Molecular simplification of 1,4-diazabicyclo[4.3.0]nonan-9-ones gives piperazine derivatives that maintain high nootropic activity. J Med Chem 2000;43:4499-507.
106. Lenzi O, Colotta V, Catarzi D, Varano F, Filacchioni G, Martini C, et al. 4-Amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. J Med Chem 2006;49:3916-25.
107. Morizzo E, Capelli F, Lenzi O, Catarzi D, Varano F, Filacchioni G, et al. Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach:from triazoloquinoxaline to a pyrimidine skeleton as a key study. J Med Chem 2007;50:6596-606.
108. Poli D, Catarzi D, Colotta V, Varano F, Filacchioni G, Daniele S, et al. The identification of the 2-phenylphthalazin-1(2H)-one scaffold as a new decorable core skeleton for the design of potent and selective human A3 adenosine receptor antagonists. J Med Chem 2011; 54:2102-13.
109. Colotta V, Catarzi D, Varano F, Capelli F, Lenzi O, Filacchioni G, et al. New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. J Med Chem 2007;50:4061-74.
110. Lenzi O, Colotta V, Catarzi D, Varano F, Poli D, Filacchioni G, et al. 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists:new insights into the receptor-antagonist recognition. J Med Chem 2009; 52:7640-52.
111. Cheong SL, Dolzhenko A, Kachler S, Paoletta S, Federico S, Cacciari B, et al. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolopyrimidines as potent and highly selective hA3 adenosine receptors antagonists:new insights into structure-affinity relationship and receptor-antagonist recognition. J Med Chem 2010;53:3361-75.
112. Venkatesan G, Paira P, Cheong SL, Vamsikrishna K, Federico S, Klotz KN, et al. Discovery of simplified N2-substituted pyrazolo[3,4-d]pyrimidine derivatives as novel adenosine receptor antagonists:efficient synthetic approaches, biological evaluations and molecular docking studies. Bioorg Med Chem 2014;22:1751-65.
113. Barr SC, Warner KL, Kornreic BG, Piscitelli J, Wolfe A, Benet L, et al. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob Agents Chemother 2005;49:5160-1.
114. Ferreira RS, Simeonov A, Jadhav A, Eidam O, Mott BT, Keiser MJ, et al. Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors. J Med Chem 2010;53:4891-905.
115. Braga SF, Martins LC, da Silva EB, Sales Junior PA, Murta SM, Romanha AJ, et al. Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification. Bioorg Med Chem 2017;25:1889-900.
116. Montagnoli A, Tenca P, Sola F, Carpani D, Brotherton D, Albanese C, et al. Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells. Cancer Res 2004;64:7110-6.
117. Swords R, Mahalingam D, O'Dwyer M, Santocanale C, Kelly K, Carew J, et al. Cdc7 kinaseda new target for drug development. Eur J Cancer 2010;46:33-40.
118. Vanotti E, Amici R, Bargiotti A, Berthelsen J, Bosotti R, Ciavolella A, et al. Cdc7 kinase inhibitors:pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships. J Med Chem 2008;51:487-501.
119. Hughes S, Elustondo F, Di Fonzo A, Leroux FG, Wong AC, Snijders AP, et al. Crystal structure of human CDC7 kinase in complex with its activator DBF4. Nat Struct Mol Biol 2012;19:1101-7.
120. Menichincheri M, Bargiotti A, Berthelsen J, Bertrand JA, Bossi R, Ciavolella A, et al. First Cdc7 kinase inhibitors:pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem 2009;52:293-307.
121. Menichincheri M, Albanese C, Alli C, Ballinari D, Bargiotti A, Caldarelli M, et al. Cdc7 kinase inhibitors:5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J Med Chem 2010;53:7296-315.
122. Mahajan R. Bedaquiline:first FDA-approved tuberculosis drug in 40 years. Int J Appl Basic Med Res 2013;3:1-2.
123. Preiss L, Langer JD, Yildiz Ö, Eckhardt-Strelau L, Guillemont JE, Koul A, et al. Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline. Sci Adv 2015;1:e1500106.
124. He C, Preiss L, Wang B, Fu L, Wen H, Zhang X, et al. Structural simplification of bedaquiline:the discovery of 3-(4-(N,Ndimethylaminomethyl)phenyl)quinoline-derived antitubercular lead compounds. ChemMedChem 2017;12:106-19.
125. Bonfils G, Jaquenoud M, Bontron S, Ostrowicz C, Ungermann C, De Virgilio C. Leucyl-tRNA synthetase controls TORC1 via the EGO complex. Mol Cell 2012;46:105-10.
126. Han JM, Jeong SJ, Park MC, Kim G, Kwon NH, Kim HK, et al. Leucyl-tRNA synthetase is an intracellular leucine sensor for the mTORC1-signaling pathway. Cell 2012;149:410-24.
127. Yoon S, Kim JH, Kim SE, Kim C, Tran PT, Ann J, et al. Discovery of leucyladenylate sulfamates as novel leucyl-tRNA synthetase (LRS)-targeted mammalian target of rapamycin complex 1 (mTORC1) inhibitors. J Med Chem 2016;59:10322-8.
128. Yoon S, Kim JH, Koh Y, Tran PT, Ann J, Yoon I, et al. Discovery of simplified leucyladenylate sulfamates as novel leucyl-tRNA synthetase (LRS)-targeted mammalian target of rapamycin complex 1 (mTORC1) inhibitors. Bioorg Med Chem 2017;25:4145-52.
129. Hurdle JG, O'Neill AJ, Chopra I. Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents. Antimicrob Agents Chemother 2005;49:4821-33.
130. Cochrane RV, Norquay AK, Vederas JC. Natural products and their derivatives as tRNA synthetase inhibitors and antimicrobial agents. MedChemComm 2016;7:1535-45.
131. Vondenhoff GH, Van Aerschot A. Aminoacyl-tRNA synthetase inhibitors as potential antibiotics. Eur J Med Chem 2011;46:5227-36.
132. Silvian LF, Wang J, Steitz TA. Insights into editing from an ile-tRNA synthetase structure with tRNAile and mupirocin. Science 1999;285:1074-7.
133. Teng M, Hilgers MT, Cunningham ML, Borchardt A, Locke JB, Abraham S, et al. Identification of bacteria-selective threonyl-tRNA synthetase substrate inhibitors by structure-based design. J Med Chem 2013;56:1748-60.
134. Torres-Larios A, Dock-Bregeon AC, Romby P, Rees B, Sankaranarayanan R, Caillet J, et al. Structural basis of translational control by Escherichia coli threonyl tRNA synthetase. Nat Struct Biol 2002;9:343-7.
135. Zhang F, Du J, Wang Q, Hu Q, Zhang J, Ding D, et al. Discovery of N-(4-sulfamoylphenyl)thioureas as Trypanosoma brucei leucyl-tRNA synthetase inhibitors. Org Biomol Chem 2013;11:5310-24.
136. Charlton MH, Aleksis R, Saint-Leger A, Gupta A, Loza E, Ribas de Pouplana L, et al. N-Leucinyl benzenesulfonamides as structurally simplified leucyl-tRNA synthetase inhibitors. ACS Med Chem Lett 2018;9:84-8.
137. Troxler T, Hurth K, Mattes H, Prashad M, Schoeffter P, Langenegger D, et al. Discovery of novel non-peptidic β-alanine piperazine amide derivatives and their optimization to achiral, easily accessible, potent and selective somatostatin sst1 receptor antagonists. Bioorg Med Chem Lett 2009;19:1305-9.
138. Hoyer D, Nunn C, Hannon J, Schoeffter P, Feuerbach D, Schuepbach E, et al. SRA880, in vitro characterization of the first non-peptide somatostatin sst1 receptor antagonist. Neurosci Lett 2004;361:132-5.
139. Singh S, Roy KK, Khan SR, Kashyap VK, Sharma A, Jaiswal S, et al. Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating. M. tuberculosis. Bioorg Med Chem 2015;23:742-52.